Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

Successful End of Phase 2 Meeting with the FDA for the Fabry Program and

Initiation of Phase 2 Clinical Trial in Pompe are Highlights for the

Quarter

CRANBURY, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the second quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.41 per share ($0.33 per share on a non-GAAP basis) for the three months ended June 30, 2008. As of June 30, 2008, cash, cash equivalents, and marketable securities totaled $145.0 million.

"The second quarter of 2008 was significant for Amicus. We initiated a Phase 2 trial of AT2220 for the treatment of Pompe disease, which is the third product from our pharmacological chaperone platform to enter Phase 2 development. We also successfully completed an End of Phase 2 meeting with the FDA related to our development of Amigal for the treatment of Fabry Disease," said John F. Crowley, President and CEO of Amicus Therapeutics. "In the second half of 2008, we will be focused on finalizing the regulatory plan in Fabry as well as executing on our Gaucher and Pompe Phase 2 clinical programs, and we have tightened our financial outlook as well by reducing our anticipated 2008 cash burn."

Program Advancements

Fabry Disease:

Amigal(TM) (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. Previous
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 According ... Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, ... & Indication (AF, VT, WPW) - Global Forecasts to ... expected to reach around ~$4.73 Billion by 2019 with ... 2014 to 2019. Browse   90 ...
(Date:3/27/2015)... , March 27, 2015  RXi Pharmaceuticals ... MirImmune LLC, today announced that they have ... RXi,s novel and proprietary sd-rxRNA® technology for ... The collaboration has the potential to result ... cancer treatments that could be a significant ...
(Date:3/27/2015)... -- Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator ... imaging centers in China , ... under which Concord Medical Services (International) Pte Ltd, ... to acquire the Fortis Surgical Hospital from Fortis ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
... ClinOps, LLC, a customer service focused clinical research ... the company as Senior Vice President of Clinical ... 28 years of clinical research experience in multiple ... central nervous system, oncology, etc. , In her ...
... ORANGE COUNTY, Calif., Oct. 26 Beckman Coulter, Inc. (NYSE: ... products that simplify, automate, and innovate complex biomedical testing, announced ... , Oppenheimer & Co. Healthcare Conference - Wednesday, November ... Conference - Friday, November 13, 2009 at 11:00 a.m. ET ...
Cached Medicine Technology:ClinOps, LLC Enhances Senior Management Team With Addition of Connie Andrews as Senior Vice President of Clinical Operations 2
(Date:3/29/2015)... Birmingham, Lake Orion, Clarkston, Metamora, MI. (PRWEB) March 29, ... affiliated with Beaumont Hospital, offers comprehensive menopause treatment. ... patients in that area a closer hospital option. ... Mercy Oakland and McLaren Oakland. , Menopause ... they age. The term "menopause" can describe any of ...
(Date:3/29/2015)... The Claudia Cohen Research Foundation ... today that Dr. Beth Y. Karlan has been selected ... Foundation Prize for Outstanding Gynecologic Researcher. The $50,000 prize ... 46th Annual Meeting on Women's Cancer in Chicago. , ... Program at the Samuel Oschin Comprehensive Cancer Institute and ...
(Date:3/29/2015)... 29, 2015 Final Cut Pro ... from Pixel Film Studios, entitled TranSports. , “TranSports ... for Final Cut Pro X,” said Christiana Austin, CEO ... tools needed to effortlessly transition using this cool sports ... new and uniquely styled transition pack for Final Cut ...
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... March 28, 2015 The California-based leading ... for every customer shopping on UniWigs during the Easter ... be a big promotion on April Fools’ Day. , ... is just around the corner. Easter Festival, with religious ... is a major holiday after Christmas. The best wig ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Menopause 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2
... This release is available in Spanish . ... the basis of a number of treatments against cancer. Nevertheless, it ... retinoic acid syndrome, present in 25 % of cases and which ... of RA, has meant a considerable advance due to its greater ...
... of smoking cessation treatments are currently available for the ... smoking each year, but success rates vary widely. Despite ... smoking cessation treatment are needed to help smokers pick ... A major new personalized medicine clinical trial, led by ...
... By Alan Mozes HealthDay Reporter , TUESDAY, Sept. ... dentists use can expose children to the controversial chemical bisphenol ... short-lived and it remains unclear whether or not it poses ... contain pure BPA, saliva can cause the fillings and sealants ...
... By Amanda Gardner HealthDay Reporter , ... that derives fats and proteins from vegetable sources rather ... Comparing the two types of diets over two decades, ... reduced rates of death from cardiovascular disease and cancer, ...
... 6, 2010) In the first human study of ... years, researchers found psilocybin, an hallucinogen which occurs ... of patients with advanced-stage cancer and anxiety, according to ... General Psychiatry. Patients enrolled in the study at ...
... higher blood levels of chemicals used in the production ... to have elevated total and LDL cholesterol levels, according ... Archives of Pediatrics & Adolescent Medicine , one of ... man-made compounds known as perfluoroalkyl acidsincluding perfluorooctanoic acid (PFOA) ...
Cached Medicine News:Health News:In-depth investigation on the capacity of 4-HPR to induce death of tumor cells 2Health News:Penn receives $12 million NIH grant to research personalized approach to smoking cessation 2Health News:Fillings, Sealants May Leach BPA Into Kids' Mouths 2Health News:Fillings, Sealants May Leach BPA Into Kids' Mouths 3Health News:Low-Carb Diets Heavy on Meat May Raise Health Risks 2Health News:LA BioMed research finds hallucinogen can safely ease anxiety in advanced-stage cancer patients 2Health News:Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: